CA2569964A1 - Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same - Google Patents

Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same Download PDF

Info

Publication number
CA2569964A1
CA2569964A1 CA002569964A CA2569964A CA2569964A1 CA 2569964 A1 CA2569964 A1 CA 2569964A1 CA 002569964 A CA002569964 A CA 002569964A CA 2569964 A CA2569964 A CA 2569964A CA 2569964 A1 CA2569964 A1 CA 2569964A1
Authority
CA
Canada
Prior art keywords
composition
sumatriptan succinate
molar concentration
sodium caprate
absorption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002569964A
Other languages
French (fr)
Inventor
Salah U. Ahmed
Lianli Li
Venkatesh Naini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Womens Health Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2569964A1 publication Critical patent/CA2569964A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Abstract

The present invention is directed to pharmaceutical compositions comprising sumatriptan succinate and sodium caprate for increased absorption of sumatriptan succinate across biological membranes. The invention is also directed to methods of making the pharmaceutical compositions and uses thereof.

Description

FORMULATIONS OF SUMATRIPTAN FOR ABSORPTION
ACROSS BIOLOGICAL MEMBRANES, AND METHODS OF

Background of the Invention Field of the Invention [0001] The present invention is directed to pharmaceutical compositions comprising sumatriptan succinate and sodium caprate for increased absorption of sumatriptan succinate- across biological membranes. The invention is also directed to methods of making the pharmaceutical compositions and uses thereof.

Background Art [0002] Sumatriptan is a selective 5-hydroxytryptamine 1D (5-HTID) receptor agonist useful for treatment of migraine. Sumatriptan is also known as 3-[2-(dimethylamino)ethy.l]-N-methyl-indole-5-methanesulphonamide.
[0003] Pharmaceutical preparations containing sumatriptan or salts of sumatriptan are described in U.S. Patent Nos. 4,816,470; 4,994,483;
5,037,845; 5,270,333; 5,288,498; 5,307,953; 5,393,773; 5,447,729; 5,554,639;
5,705,520; 5,863,559; 6,020,001; 6,255,502; 6,294,192; and 6,368,627;
U.S. Patent Appl. Pub. Nos. 2003/0013753; 2003/0185761; and 2003/0190286; WO 98/02186; WO 01/39836; and DE 4314976.
[0004] An injectable form of sumatriptan succinate, Formula I, was approved by the U.S. Food and Drug Administration (FDA) for acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes:
CH2CH2N(CH3)2 CH3NHSO2CH2 1::)3N COOH
H iH2 C\2 COOH
[0005] An oral tablet form of sumatriptan succinate and a nasal spray form of sumatriptan base were also approved by the FDA for acute treatment of migraine attacks, with or without aura.
[0006] Although subcutaneous injection of sumatriptan succinate provides rapid migraine control, it is an invasive method of administration and is disliked and poorly tolerated by many patients. Administration of an oral tablet of sumatriptan succinate is sometimes unsuitable for patients because it can cause severe migraine-related vomiting. The intranasal spray currently available does not significantly improve the bioavailability of sumatriptan.
The bioavailability of sumatriptan using the nasal spray is 17% whereas it is 15% for the oral tablet. Following mucociliar clearance, sumatriptan administered by the intranasal spray is primarily absorbed by the oral route after 10-15 min of residence time on nasal mucosa. Further, nasal absorption is associated with high variability for patients suffering from cold or allergy.
There remains a need for pharmaceutical compositions of sumatriptan with ease of administration and improved bioavailability.

Brief Summary of the Invention [0007] The present invention is directed to a method of making a pharmaceutical composition for rapid transmucosal delivery comprising sumatriptan succinate and sodium caprate, the method comprising mixing sumatriptan succinate and sodium caprate to form a mixture, wherein a molar ratio (M) of a molar concentration of sodium caprate to a molar concentration of sumatriptan succinate is about 0.1 or greater, wherein absorption of sumatriptan succinate across a biological membrane (FS) is equal to Fo + x ln(M), wherein Fo is a steady state flux value of the absorption when the molar ratio of a molar concentration of sodium caprate to a molar concentration of sumatriptan succinate is 1, and wherein x is an enhancement factor. In some embodiments, the method further comprises compressing the mixture into a pharmaceutical composition, wherein the mixture can be a dry mixture, a wet granulate, a gel, a paste, a solution or combinations thereof.
[0008] The invention is also directed to a method of making a pharmaceutical composition for rapid transmucosal delivery comprising sumatriptan succinate and sodium caprate, the method comprising dispersing sumatriptan succinate and sodium caprate in water or a solvent to prepare a mixture, and casting the mixture to form a pharmaceutical composition, wherein a molar ratio (M) of a molar concentration of sodium caprate to a molar concentration of sumatriptan succinate is about 0.1 or greater, wherein absorption of sumatriptan succinate across a biological membrane (FS) is equal to Fo + ic ln(M), wherein Fo is a steady state flux value of the absorption when the molar ratio of a molar concentration of sodium caprate to a molar concentration of sumatriptan succinate is 1, and wherein the x is an enhancement factor. In some embodiments, the mixture is spray dried to form a second mixture. In some embodiments, the method fiirther comprises compressing the second mixture into a pharmaceutical composition.
[0009] The invention is also directed to a method of treating migraine, the method comprising administering a pharmaceutical composition comprising sumatriptan succinate and sodium caprate, wherein a molar ratio (M) of a molar concentration of sodium caprate to a molar concentration of sumatriptan succinate is about 0.1 or greater, wherein the absorption of sumatriptan succinate across a biological membrane (FS) is equal to Fo + x ln(M), wherein Fo is a steady state flux value of the absorption when the molar ratio of a molar concentration of sodium caprate to a molar concentration of sumatriptan succinate is 1, and wherein x is an enhancement factor, to a person in need of the treatment. In some embodiments, sodium caprate is the absorption enhancer.
[0010] The invention is also directed to a method of treating cluster headache episodes, the method comprising administering a pharmaceutical composition comprising sumatriptan succinate and sodium captrate, wherein a molar ratio (M) of a molar concentration of sodium caprate to a molar concentration of sumatriptan succinate is about 0.1 or greater, wherein the absorption of sumatriptan succinate across a biological membrane (FS) is equal to Fo + ic ln(M), wherein Fo is a steady state flux value of the absorption when the molar ratio of a molar concentration of sodium caprate to a molar concentration of sumatriptan succinate is 1, and wherein ic is an enhancement factor, to a person in need of the treatment [0011] The present invention is also directed to a pharmaceutical composition for rapid transmucosal delivery comprising sumatriptan succinate and sodium caprate, wherein the molar concentration of the sodium caprate is about 1 M
to about 250 mM.
[0012] The present invention is also directed to a pharmaceutical composition for rapid transmucosal delivery comprising sumatriptan succinate and sodium caprate, wherein the amount of sodium caprate per dosage unit is about 1 mol to about 250 mmol.

Brief Description of the Figures [0013] FIG. 1 provides a process flow chart for a method of manufacturing the pharmaceutical compositions of the invention by a dry mixing process.
[0014] FIG. 2 provides a process flow chart for a method of manufacturing the pharmaceutical compositions of the invention by a wet granulation process.
[0015] FIG. 3 is a graph that shows the relationship between the steady state flux of absorption (Fs) of sumatriptan succinate across a buccal membrane and the molar ratio (M) of the molar concentration of sodium caprate to the molar concentration of sumatriptan succinate. The graph shows ln(M) on the x-axis and FS (ng/cm2/min) on the y-axis.
[0016] FIG. 4A provides a chromatogram from a high performance liquid chromatography (HPLC) analysis of a standard solution of sumatriptan succinate alone. The x-axis shows retention time (mins) and the y-axis shows absorbance (in absorbance units (AU)) at 288 nm.
[0017] FIG. 4B provides a chromatogram from an HPLC analysis of a sample taken from the receptor-side of a side-by-side diffusion experiment. The x-axis shows retention time (mins) and the y-axis shows absorbance (AU) at 288 nm.
[0018] FIG. 4C provides absorbance data for the major peak seen in FIG. 4A.
The x-axis shows wavelength (nm) and the y-axis shows AU.
[0019] FIG. 4D provides absorbance data for the major peak seen in FIG. 4B.
The x-axis shows wavelength (nm) and the y-axis shows AU.
[0020] FIG. 5 provides a graph showing the relationship between the latent heat of fusion, AHf, and the weight percent of sumatriptan succinate in samples containing varying amounts of sumatriptan succinate. The x-axis shows the weight % (wt %) of sumatriptan succinate and the y-axis shows AHf in joules/gram (J/g) from the peak observed at about 170 C during differential scanning calorimetry (DSC).
[0021] FIG. 6A provides a chromatogram from an HPLC analysis of a standard solution of sumatriptan succinate alone. The x-axis shows retention time (mins) and the y-axis shows absorbance (AU) at 288 nm.
[0022] FIG. 6B provides a chromatogram from an HPLC analysis of a dry mixture of sumatriptan succinate and sodium caprate. The x-axis shows retention time (mins) and the y-axis shows absorbance (AU) at 288 nm.
[0023] FIG. 6C provides absorbance data for the major peak seen in FIG. 6A.
The x-axis shows wavelength (nm) and the y-axis shows AU.
[0024] FIG. 6D provides absorbance data for the major peak seen in FIG. 6B.
The x-axis shows wavelength (nm) and the y-axis shows AU.
[0025] FIG. 7A provides a chromatogram from an HPLC analysis of a standard solution of sumatriptan succinate alone. The x-axis shows retention time (mins) and the y-axis shows absorbance (AU) at 288 nm.
[0026] FIG. 7B provides a chromatogram from an HPLC analysis of a wet mixture of sumatriptan succinate and sodium caprate. The x-axis shows retention time (mins) and the y-axis shows absorbance (AU) at 288 nm.
[0027] FIG. 7C provides absorbance data for the major peak seen in FIG. 7A.
The x-axis shows wavelength (nm) and the y-axis shows AU.
[0028] FIG. 7D provides absorbance data for the major peak seen in FIG. 7B.
The x-axis shows wavelength (nm) and the y-axis shows AU.
[0029] FIG. 8 provides a plasma concentration versus time curve for a sumatriptan study performed in dogs.

Detailed Description of the Invention [0030] The invention is directed to a pharmaceutical composition for rapid transmucosal delivery comprising a drug (e.g., sumatriptan succinate) and an absorption enhancer (e.g., sodium caprate) wherein a molar ratio (M) of a molar concentration of the absorption enhancer to a molar concentration of the drug is about 0.1 or greater, wherein absorption of the drug across a biological membrane (FS) is equal to Fo+x ln(M), wherein Fo is a steady state flux value of the absorption when the molar ratio of a molar concentration of the absorption enhancer to a molar concentration of the drug is 1, and wherein x is an enhancement factor.
[0031] The drug in the pharmaceutical compositions include but are not limited to inorganic and organic salts of sumatriptan such as hydrochloride, hydrobromide, sulphate, nitrate, phosphate, formate, mesylate, citrate, benzoate, fumarate, maleate, tartrate, hemisuccinate, methanesulphonate, succinate, and combinations thereof. In some embodiments the drug is sumatriptan succinate.
[0032] Absorption of a drug involves passage of the drug across biological membranes whereby a cell, tissue or organ takes up the drug. Absorption is also referred to as the rate and extent to which a drag leaves its site of administration. The physicochemical properties of the molecules in the pharmaceutical composition as well as that of the membranes affect the absorption of drugs across membranes.
[0033] Biological membranes are sheets of tissue that include but are not limited to membranes that provide a pliable surface lining far protecting or partitioning organs and structures in the body. As used herein, a biological membrane is an epithelial membrane. Epithelial membranes include but are not limited to coverings or linings of the outer layer of skin and some internal organs, e.g., digestive, respiratory, reproductive and urinary systems.
Epithelial membranes include the lining of body cavities. Epithelial membranes include but are not limited to oral, buccal, sublingual, gingival, palatal, nasal, nasopharynxal, oropharynxal, conjunctival, transdermal, vaginal and gastrointestinal membranes. In some embodiments, the structure can be a cellular structure.
[0034] In some embodiments, the biological membrane is a buccal mucosal membrane. In some embodiments, the invention is directed to a pharmaceutical composition comprising sumatriptan succinate and sodium caprate in dosage forms suitable for increased absorption across a buccal mucosal membrane. The advantages of buccal delivery are that it bypasses the first-pass effect associated with peroral delivery of sumatriptan, provides for ease of administration, and provides for the likelihood of rapid-onset of anti-migraine effect.
[0035] In some embodiments, the invention is directed to pharmaceutical compositions for the rapid transmucosal delivery of a drug, e.g., sumatriptan.
Rapid transmucosal delivery means that the drug is delivered transmucosally with a rate of absorption which exceeds that of the sumatriptan oral tablet (IMITREX).
[0036] Absorption enhancers are agents that increase drug absorption across biological membranes. Absorption enhancers for use in pharmaceutical compositions of the present invention include but are not limited to sodium caprate, sodium caprylate, sodium laurate, sodium lauryl sulfate and combinations thereof.
[0037] In some embodiments, the absorption enhancer is sodium caprate. In some embodiments, the molar concentration of sodium caprate can be about I M to about 250 mM. In some embodiments, the molar concentration of sodium caprate can be about 1 mM to about 200 mM. In some embodiments, the molar concentration of sodium caprate can be about 1 mM to about 150 mM. In some embodiments, the molar concentration of sodium caprate can be about 10 mM to about 250 mM. In some embodiments, the molar concentration of sodium caprate can be about 10 mM to about 200 mM. In some embodiments, the molar concentration of sodium caprate can be about mM to about 100 mM. In some embodiments, the molar concentration of sodium caprate can be about 10 mM to about 80 mM.
[0038] In some embodiments, the amount of sodium caprate per dosage unit is about 1 mol to about 250 mmol. In some embodiments, the amount of sodium caprate per dosage unit is about 1 mmol to about 200 mmol. In some embodiments, the amount of sodium caprate per dosage unit is about 1 mmol to about 150 mmol. In some embodiments, the amount of sodium caprate per dosage unit is about 10 mmol to about 250 mmol. In some embodiments, the amount of sodium caprate per dosage unit is about 10 mmol to about 200 mmol. In some embodiments, the amount of sodium caprate per dosage unit is about 10 mmol to about 100 mmol.
[0039] The molar ratio (M) is the molar concentration of the absorption enhancer to the molar concentration of the drug, e.g., sumatriptan succinate.
In some embodiments, the value of M is about 0.1 or greater, or about 0.5 or greater, or about 1.0 or greater. In some embodiments, the value of M is about 0.1 to about 15. In some embodiments, the value of M is about 0.5 to about 10. In some embodiments, the value of M is about 0.1 to about 15. In some embodiments, the value of M is about 0.5 to about 10. In some embodiments, the value of M is about 0.8 to about 7. In some embodiments, the value of M
is about 1.2 to about 7. In some embodiments, the value of M is about 1.5 to about 7.
[0040] FS is a steady state flux value of the absorption of a drug, e.g., sumatriptan succinate, across a biological membrane and is equal to Fo + x ln(M). The value of FS can be determined experimentally for the pharmaceutical compositions of the present invention, e.g., by performing side-by-side diffusion experiments over a varying range of molar ratios of the molar concentration of the absorption enhancer to the molar concentration of the drug (e.g., sumatriptan succinate) while maintaining substantially constant the physicochemical characteristics of the biological membrane. In a side-by-side diffusion experiment, there exists a reservoir on each side of the test biological membrane. One reservoir, referred to as the donor-side, contains the drug with or without the absorption enhancer, whereas the other side, referred to as the receptor-side, has only buffer. The diffusion of drug, e.g., sumatriptan succinate, from the donor-side to the receptor-side is monitored over a period of time. The steady state flux of absorption, FS, is calculated by the formula, FS = (dQ/dt)/A = (dC/dt) x (V/A), wherein Q is the amount of drug permeated, C is the concentration of the drug, A is the permeation area, V is the chamber volume in a side-by-side diffusion cell, and t is the time period over which the drug permeation is monitored. FS can be determined from the slope of the line attained from plotting the cumulative amount of drug permeated per unit area as a function of time.
[0041] The results of such an experiment measuring the absorption of a drug, e.g., sumatriptan succinate, across a biological membrane can be expressed as FS as a function of ln(M). The value of FS can vary depending on, e.g., the molar ratio (M) of the pharmaceutical composition, the physicochemical properties of the biological membrane such as thickness and type of the membrane, the diffusion medium used in the experiments, the concentration of drug in the donor-side in side-by-side diffusion experiments, the speed at which the solutions are stirred in a side-by-side diffusion experiment, the volume of sample removed from the receptor-side for sampling, and the frequency with which the samples are removed from the receptor-side for sampling.
[0042] Fo is a steady state flux value of absorption of drug (e.g., sumatriptan succinate) across a biological membrane when the value of the molar ratio of a molar concentration of the absorption enhancer (e.g., sodium caprate) to the molar concentration of drug is 1. Fo is constant for a given experimental condition and is the intercept of FS (y-axis) versus ln(M) (x-axis).
[0043] The value of Fo can be determined experimentally, e.g., by performing side-by-side diffusion experiments measuring the permeability of the drug across a biological membrane for the pharmaceutical composition of the invention. However, the specific value of Fo can vary depending on changes in the experimental conditions, e.g., the physicochemical properties of the biological membrane, the diffusion medium used in the experiments, the concentration of drug in the donor-side in side-by-side diffusion experiments, the speed at which the solutions are stirred in a side-by-side diffusion experiment, the volume of sample removed from the receptor-side for sampling, and the frequency with which the samples are removed from the receptor-side for sampling. In some embodiments, when, e.g., sodium caprate is the absorption enhancer, the value of Fo can be about 100 ng/cm2/min to about 1000 ng/cm2/min, about 150 ng/cm2/min to about 950 ng/cm2/min, about 300 ng/cm2/min to about 550 ng/cma/min, or about 420 ng/cm2/min.
[0044] The enhancement factor x is constant for a given experimental condition and is the slope of Fs (y-axis) versus ln(M) (x-axis). The value of K
can be determined experimentally, e.g., by performing side-by-side diffusion experiments for the pharmaceutical compositions of the invention. However, the value of x can vary depending on changes in the experimental conditions, e.g., the physicochemical properties of the biological membrane, the diffusion medium used in the experiments, the concentration of drug in the donor-side in side-by-side diffusion experiments, the speed at which the solutions are stirred in a side-by-side diffusion experiment, the volume of sample removed from the receptor-side for sampling, and the frequency with which the samples are removed from the receptor-side for sampling. In some embodiments, when, e.g., sodium caprate is the absorption enhancer, the value of x can be about 1000 ng/cm2/min to about 2000 ng/cm2/min, about 1200 ng/cm2/min to about 1500 ng/cm2/min, or about 1300 ng/cm2/min.
[0045] The absorption data obtained for a range of molar ratios can be subjected to regression analysis. Regression analysis is a group of statistical methods to examine the degree of association between one variable (or set of variables) and another variable (or set of variables). Regression analysis methods are generally described in Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, 21 St ed. (2004). Regression analysis of the absorption data provides a range of values for a correlation coefficient (r). The correlation coefficient provides a measure of the relationship between the two variables. For the pharmaceutical compositions of the invention, determining the correlation coefficient provides a measure of the relationship between the absorption of drug (e.g., sumatriptan succinate) across a biological membrane and the natural logarithmic value of the molar ratio of the molar concentration of an absorption enhancer to the molar concentration of sumatriptan succinate (ln(M)). In some embodiments, when, e.g., sodium caprate is the absorption enhancer, regression analysis provides a correlation coefficient (r) of about 0.9 to about 1, or about 0.95 to about 1.
[0046] The pharmaceutical compositions of the invention can be formulated with one or more carriers or excipients, such as but not limited to hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, polyvinylpyrrolidone, polyethylene glycol, vegetable oil, polyols, lactose and combinations thereof. As one of slcill in the are can readily determine, many carriers, e.g., polymers, can be used in the present invention depending on the molecular weight of the polymer, the viscosity of the polymer, and the amount of the polymer in the pharmaceutical composition.
[0047] The pharmaceutical compositions of the invention can include one or more mucoadhesive polymers. Mucoadhesive polymers have physicochemical properties suitable for adhering to biological membranes.

Mucoadhesive polymers are natural or synthetic polymers that adhere to mucosal membranes by means of hydrogen bonds, ionic interactions, physical entanglements, and combinations thereof. In some embodiments, mucoadhesive polymers adhere to wet mucosal epithelial membranes.
Mucoadhesive substances for use in the pharmaceutical compositions of the invention can include but are not limited to poly(ethylene oxide), polyvinylpyrrolidone, copovidone, carbomer, polycarbophil, hydroxypropyl cellulose, hydroxyethyl cellulose, sodium carboxymethyl cellulose, polyvinyl alcohol, and combinations thereof.
[0048] The pharmaceutical compositions of the invention can comprise one or more diluents. A diluent is any inert substance, or mixture of substances, added to increase the bulk of the pharmaceutical formulation in order to make the solid oral dosage form a practical size for administration or compression.
Diluents include but are not limited to lactose, starch, polyethylene glycol, maltodextrin, dextrose, mannitol, xylitol, other polyols, and combinations thereof.
[0049] The pharmaceutical compositions of the invention can be formulated for non-parenteral administration. Exemplary non-parenteral routes include, but are not limited to, the buccal, sublingual, nasal, transdermal, oral, or other transmucosal route. The pharmaceutical compositions of this invention can also be formulated for various dosage forms that include but are not limited to a tablet, disk, patch, film, wafer, gel, paste and solution dosage fonns.
Suitable solution dosage forms for the present invention include, but are not limited to, a nasal spray, a nasal drop, a sublingual solution, or any other solution which can be administered transmucosally.
[0050] The invention is also directed to methods of making pharmaceutical compositions comprising a drug (e.g., sumatriptan succinate) and an absorption enhancer (e.g., sodium caprate), the method comprising mixing the drug and the absorption enhancer to form a mixture, wherein a molar ratio (M) of a molar concentration of the absorption enhancer to a molar concentration of the drug is about 0.1 or greater, wherein absorption of the drug across a biological membrane (Fs) is equal to Fo + x ln(M), wherein Fo is a steady state flux value of the absorption when the molar ratio of a molar concentration of the absorption enhancer to a molar concentration of the drug is 1, and wherein ic is an enhancement factor.
[0051] Methods of preparing various pharmaceutical compositions with a certain amount of active ingredients are known, or will be apparent in light of this disclosure, to those skilled in the art. Methods of preparing the pharmaceutical compositions can incorporate other suitable pharmaceutical excipients and their formulations as described in Remington: The Science and Practice of Plzarmacy, Lippincott Williams & Wilkins, 21 St ed. (2004).
[0052] The pharmaceutical compositions of the present invention can be manufactured in a manner that is known in the art, including conventional dry or wet mixing, dissolving, or compressing processes. Pharmaceutical compositions can be obtained by combining the drug (e.g., sumatriptan succinate) and one or more absorption enhancers to form mixtures. Optionally the resulting mixture can be processed after adding suitable auxiliaries, if desired or necessary. Two exemplary methods of preparing the pharmaceutical compositions of the invention, by a dry mixing process and by a wet granulation process, are provided in FIGs. 1 and 2.
[0053] In some embodiments, the method further comprises compressing the mixture into a pharmaceutical composition, wherein the mixture is a dry mixture. In some embodiments, the method fu.rther comprises compressing the mixture into a pharmaceutical composition, wherein the mixture is a wet granulate. In some embodiments, the mixture is a gel, a paste, or a solution.
[0054] In some embodiments, the invention provides a method of making a pharmaceutical composition comprising a drug (e.g., sumatriptan succinate) and an absorption enhancer (e.g., sodium caprate), wherein the method comprises dispersing the drug and the absorption enhancer in water or a solvent to prepare a mixture, and casting the mixture to form a pharmaceutical composition, wherein a molar ratio (M) of a molar concentration of the absorption enhancer to a molar concentration of the drug is about 0.1 or greater, wherein the steady state flux of absorption of the drug across a biological membrane (FS) is equal to Fo + x ln(M), wherein Fo is a steady state flux value of absorption when the molar ratio of a molar concentration of the absorption enhancer to a molar concentration of the drug is 1, and wherein x is an enhancement factor. In some embodiments, the mixture can be spray dried to form a second mixture. In some embodiments, the method further comprises compressing the second mixture into a pharmaceutical composition.
[0055] Various solvents can be used. In some embodiments, the solvents used to prepare the mixtures include volatile or dryable solvents, such as, water, isopropanol, ethanol, methanol, acetone, ethyl acetate, and combinations thereof.
[0056] Casting of the mixture can be performed during the preparation of the pharmaceutical compositions. Casting refers to the process of spreading the mixture onto suitable devices and drying. In some embodiments, the dried components are cut into uniform pieces.
[0057] In some embodiments, the invention is directed to pharmaceutical compositions made by the methods of the invention. The enhancement of sumatriptan succinate absorption was related to the molar ratio of the molar concentration of sodium caprate to the molar concentration of sumatriptan succinate rather than to the method of preparation of the composition.
[0058] The pharmaceutical compositions of the invention can be used for the treatment of migraine attacks, with or without aura, or for the treatment of cluster headache episodes in adults as well as children. In some embodiments, the invention comprises a method of treating migraine, the method comprising administering the pharmaceutical compositions of the invention to a person in need of the treatment.
[0059] As used herein, "about" refers to plus or minus 10% of the indicated number.
[0060] All of the various embodiments or options described herein can be combined in any and all variations.
[0061] The following Examples serve only to illustrate the invention and are not to be construed in anyway to limit the invention.

Examples Example 1 Enhancement of Sumatriptan Succinate Absorption Across the Buccal Membrane [0062] The steady state flux of absorption of sumatriptan succinate, FS, across a buccal epithelial membrane ranging in thickness from about 400 nanometers to about 600 nanometers was measured. Freshly prepared buccal tissue from pigs was used to prepare the buccal epithelial membrane. A dermatometer was used to obtain the buccal epithelial membrane by separating it from the underlying connective tissue. The buccal membranes were used within 3-4 hours of removal of buccal tissue from the pigs.
[0063] The buccal epithelial membrane was mounted between side-by-side diffusion cells. The exposed area of the buccal membrane was approximately 0.64 cm2. In some experiments sumatriptan base alone or sumatriptan succinate alone in Krebs-Ringer bicarbonate (KRB) solution were dosed in the donor-side. In some experiments sumatriptan base or sumatriptan succinate was mixed with absorption enhancers in KRB solution and dosed in the donor-side. The final volume of the liquid in the donor-side was 3.5 ml and the volume in the receptor-side was 3.5 ml.
[0064] The diffusion system was maintained at 37 C throughout the experiment. At predetermined intervals over a period of 6 hours, 150 l of the solution from the receptor-side was withdrawn for HPLC analysis. The receptor-side was refilled with the same volume (150 l) of KRB solution.
[0065] HPLC analysis of the solution withdrawn from the receptor-side was performed using a Waters 2695 separation module HPLC system equipped with a reverse phase C18 column (150 mm x 3.9 mm ID, 5 m) (Waters Corp., Milford, MA). The mobile phase was 88% phosphate buffer (0.05 M
NH4H2PO4/H3PO4, pH 3.3) and 12% acetonitrile. Ultraviolet (UV) analysis was performed using a Waters 2996 photodiode array detector (Waters Corp., Milford, MA) with the wavelength set at 228 nm to detect sumatriptan succinate. The software used for HPLC assay data analysis was Millenium 32 (Waters Corp., Milford, MA).
[0066] Absorption of drug, i.e., sumatriptan succinate or sumatriptan base, across the buccal membrane, Fs, was determined from the slope of the straight line (2-6 hrs) attained from the plot of the cumulative amount of sumatriptan succinate permeated as a function of time. Microsoft Excel 2000 was used to calculate the steady state flux value of the absorption of the drug across the buccal membrane. The steady state flux (FS) =(dQ/dt)/A =(dC/dt) x (V/A), wherein Q is the amount of drug permeated, C is concentration of the drug, A
is the permeation area, V is the chamber volume, and t is the time period over which the drug permeation is monitored.
[0067] Table 1 provides the results in which sumatriptan succinate salt (SS) or sumatriptan base was mixed with sodium caprate, sodium laurate, sodium lauryl sulfate, sodium caprylate, EDTA, sodium glycocholate, lauric acid, or with lysolecithin in KRB solution and dosed in the donor-side (3.5 ml). The receptor-side contained 3.5 ml of KRB solution.

Table 1. Trans-buccal absorption of sumatriptan succinate and base across pig buccal membrane: Effect of absorption enhancers.
Composition Steady-state flux, Fs Enhancement Ratio (ng/cm /min) F's, SS+enhancer/ F's, SS alone Surnatriptan Succinate (SS) 12 mM

Salt (SS) alone 6.0 ~ 6.6 + 80 mM Na Caprate 3068.6 ~ 314.0 511 + 60 mM Na Caprate 2379.7 610.7 397 + 40 mM Na Caprate 2083.4 :L 1071.5 347 + 20 mM Na Caprate 1055.4 ~ 506.7 176 + 10 mM Na Caprate 210.4 ~ 127.1 35 + 20 mM Na Laurate 549.5 ~ 444.3 92 + 20 mM SLS 154.8 ~ 197.9 26 + 20 mM Na Caprylate 94.3 163.1 16 +20mMEDTA 26.5+20.1 4 + 20 mM Na Glycocholate 21.6 20.0 4 + 20 mM Lauric acid 19.2 10.2 3 + 20 mM Lysolecithin 18.8 22.0 3 Sunaatriptan (base) Enhancement Ratio 6.8 mM Fs, base + enhancer / Fs, base alone Base alone 1.6 +1.5 + 20 mM Na Caprate 2.0 =L 2.3 1.3 + 20 mM Lysolecithin 1.8 :L 1.1 1.1 + 20 mM Na Glycocholate 1.2 1.0 0.8 = Values are presented as means ~ SD with n? 3.
= Steady state flux, Fs, was determined from the slope of the straight line (2-6 hrs) attained from the plot of the cumulative amount of drug permeated per unit area as a function of time.
[0068] In Table l, FS, SS+enhancer is the steady state flux value of the absorption of sumatriptan succinate when the donor-side contained sumatriptan succinate and an absorption enhancer. FS, SS alone is the steady state flux value of the absorption of sumatriptan succinate when the donor-side contained sumatriptan succinate alone. FS, base+enbaaoer is the steady state flux value of the absorption of sumatriptan base when the donor-side contained sumatriptan base and an absorption enhancer. Fs, base alone is the steady state flux value of the absorption of sumatriptan base when the donor-side contained sumatriptan base alone. The enhancement ratio is the ratio of the steady state absorption of the drug, e.g., sumatriptan succinate or sumatriptan base, when mixed with an absorption enhancer to the steady state absorption of the drug alone. As seen in Table 1, sodium caprate, sodium laurate, sodium caprylate, and sodium lauryl sulfate (SLS) enhanced the permeation of sumatriptan succinate across the buccal membrane. Sodium caprate showed the most dramatic effect in enhancing sumatriptan succinate absorption. EDTA, sodium glycocholate, lauric acid, and lysolecithin showed only minor enhancing effects on the permeation of sumatriptan succinate. However, the absorption of sumatriptan base was not significantly enhanced by the absorption enhancers.
[0069] Table 2 summarizes the data from Table 1 for the experiment using sumatriptan succinate and sodium caprate, and provides values for molar ratio (M) and ln(M). The values for M were calculated from the experimental concentration of sumatriptan succinate used, i.e., 12 mM, and from the concentrations of sodium caprate used, i.e., 10 mM, 20 mM, 40 mM, 60 mM
and 80 mM. The data in Table 2 is graphically depicted in FIG. 3, which provides a plot of FS as a function of ln(M). In FIG. 3, the slope (the value for K) was 1329.2 ng/cm2/min; the intercept (the value for Fo) was 420 ng/cm2/min. Regression analysis showed that the correlation coefficient (r) was 0.9946.

Table 2. Steady state flux value (Fs) as a function of the molar ratio (M) of a molar concentration of sodium caprate to a molar concentration of sumatriptan succinate.

Na Caprate Molar Ratio (M) ln(M) Fs (ng/cm /min) (MM) 0.83 -0.18 210.4 1.67 0.51 1055.4 40 3.33 1.20 2083.4 60 5.00 1.61 2379.7 80 6.67 1.90 3068.6 Sumatriptan succinate = 12 mM
[0070] HPLC analysis was performed to compare the retention time for a standard solution of sumatriptan succinate alone (FIG. 4A) and the solution from the receptor-side of the side-by-side diffusion experiment (FIG. 4B).
The retention time for sumatriptan succinate alone was 3.479 min and the retention time for the solution from the receptor-side was 3.559 min. FIGs. 4C
and 4D provide the UV absorbance data (200-400 nm) for the major peaks observed in FIGs. 4A and FIG. 4B, respectively. In both FIGs. 4C and 4D, two peaks corresponding to 226.4 nm and 281.9 nm were observed. The UV
absorbance of the pure drug solution (FIG.4C) was similar to the UV
absorbance of the sample obtained from the receptor chamber (FIG. 4D).

Example 2 Mucoadhesive Formulations [0071] Mucoadhesion allows buccal tablets to remain in close contact with the site of drug administration. Table 3 provides three mucoadhesive formulations, Rxl to Rx3, for mucoadhesive, monolithic buccal tablets. Drug containing buccal tablets (patches) were placed on the buccal mucosa of the human volunteers, whereas, placebo buccal tablets (patches) were placed on the front upper gum of human volunteers to check residence time. Table 3 shows that the residence time of sumatriptan succinate on a buccal membrane can be varied by varying the type of mucoadhesives in the formulation. As seen in Table 3, HXF grade of hydroxypropyl cellulose (HPC) results in longer (60 min) residence time on the buccal mucosa compared to EXF grade of HPC, which exhibits lesser (30 min) residence time.

Table 3. Residence time of mucoadhesive formulations.
Ingredients Amount/Tablet (mg) Rxl Rx2 Rx3 1 Sumatriptan Succinate 10 10 10 2 Sodium Caprate 10 10 10 3 Polyethylene Glycol 8000 (PEG 8000) 38.6 38.6 38.6 4 Anhydrous Lactose, NF (DT Grade) 15 15 15 Poly(ethylene oxide) (POLYOX 301) 5 5 5 6 Povidone K3 0 (PVP K3 0) 15 5 5 7 HPC (EXF) 10 8 HPC (HXF) 10 9 Talc 2 2 2 11 Aspartame 3 3 3 12 Flavor 1.4 1.4 1.4 Total Tablet Weight (mg) 100 100 100 Residence tiine on buccal membrane 30 min 30 min 60 min [0072] A TA-XTplus Texture Analyzer (Texture Technologies Corporation, Scarsdale, NY) was used to evaluate the effect of different pharmaceutical excipients on mucoadhesion. Table 4 provides the results of experiments using different pharmaceutical excipients on mucoadhesion of 5% polyethylene oxide (POLYOX 301) (Union Carbide, Danbury, CT) in PEG 8000 based buccal tablets (formulations Rx4 through Rx13). The detachment force (g) is the force required to detach the tablet from a surface to which the tablet is attached, e.g., glass or mucosa. A buccal tablet was fixed onto the probe of a TA-XTplus Texture Analyzer and a 300 g force was applied for 2 min by pressing the tablet against a glass surface wetted by 0.1 ml purified water. The detachment force was determined by measuring the force required to detach the tablet from the glass surface.
[0073] The erosion time of the tablet matrix is a measure of the physical integrity of the drug dosage form. A standard USP dissolution apparatus type I(Paddle, 50 RPM) was used for determining the erosion time for complete erosion of the tablet in purified water (300 ml). The pharmaceutical dosage form was fixed onto the bottom of the dissolution vessel utilizing the wet adhesive property of the dosage form itself.
[0074] The results in Table 4 indicate that by varying the amount and types of mucoadhesive components in the tablet, the detachment force and erosion time of the tablet can be varied, e.g., povidone (PVP K30) and hydroxypropyl cellulose (HPC) have a synergistic effect on the mucoadhesion property of POLYOX 301.

Table 4. Detachment Force and Erosion Time of Buccal Tablets.
No. Ingredients mg/Tablet Formulation No. Rx4 Rx5 Rx6 Rx7 Rx8 Rx9 Rx10 Rxll Rx12 Rx13 1 Polyethylene 5 5 5 5 5 5 5 5 5 5 oxide (POLYOX 301) 2 PEG 8000 95 47.5 47.5 47.5 47.5 47.5 47.5 47.5 32.0 47.5 3 Maltodextrin 47.5 47.5 32.0 (M100) 4 Lactose DT 47.5 Dextrose 47.5 Anhydrous 6 HPMC (3 cps) 47.5 7 HPC (EXF) 47.5 8 PVP K30 47.5 32.0 9 Mannitol 47.5 Tabletrun 100 100 100 100 100 100 100 100 100 100 weight (mg) Detachment 157 164 189 135 133 139 284 1031 480 170 Force (g) Erosion Time 24 68 115 62 24 130 360 40 26 30 (min) Example 3 Characterization of Formulations [0075] Samples containing sumatriptan succinate alone, sodium caprate alone or compositions containing sumatriptan succinate and sodium caprate were analyzed by DSC, using a Universal V2.6D instrument from TA Instruments (Delaware, USA). In formulations prepared by the dry mixing process (FIG. 1), the location and area of the DSC thermogram peak corresponding to sumatriptan succinate were not significantly affected by the dry mixing process indicating that the crystallinity of sumatriptan succinate was not altered by the method of preparing the formulation. However, the DSC
endotherm corresponding to sumatriptan succinate was not evident in samples prepared by the wet mixing process (FIG. 2), probably due to loss of crystallinity of the drug. Samples prepared by both the dry and wet methods showed enhancement or improvement in absorption of sumatriptan succinate as a function of the molar ratio of the molar concentration sodium caprate to the molar concentration of sumatriptan succinate.
[0076] To determine the identity of peaks in the dry mixtures containing sumatriptan succinate and sodium caprate, the latent heat of fusion (AHf) of the endotherm observed at about 170 C in sumatriptan succinate alone and in the dry mixtures was examined as a function of the wt % of sumatriptan succinate. As seen in Table 5, the latent heat of fusion of peak at about 170 C
in the dry mixtures decreased as the wt % of sumatriptan succinate decreased, which indicates that the peak at about 170 C corresponds to sumatriptan succinate. In Table 5, M is the molar ratio of the molar concentration of sodium caprate to the molar concentration of sumatriptan succinate. The data in Table 5 is graphically depicted in FIG. 5. In FIG. 5, a linear relationship is observed between AHf of the dry mixtures and the wt % of sumatriptan succinate, which indicates that the peak at about 170 C in the dry mixtures corresponds to sumatriptan succinate.

Table 5. OHrWt % of sumatriptan succinate.
Molar Ratio Wt % of Peak temp. ( C) AHf (J/g) (M) Sumatriptan Succinate 1 Sumatriptan 100 170 153 succinate alone (SS) 2 Dry mixture 1 68 167 113 3 Dry mixture 3.2 40 167 85 4 Dry mixture 6.6 24 169 22 [0077] HPLC analysis was performed using a Waters 2695 separation module HPLC system equipped with a reverse phase C18 column (150 mm x 3.9 mm ID, 5 m) (Waters Corp., Milford, MA). Ultraviolet analysis was performed using a Waters 2996 photodiode array detector (Waters Corp., Milford, MA) with the wavelength set at 228 nm to detect sumatriptan succinate. The retention time was determined for a standard solution of sumatriptan succinate alone (FIG. 6A) and for a dissolved sample of a dry mixture of sodium caprate and sumatriptan succinate prepared at a molar ratio (M) of 2.1 (FIG. 6B). The retention time was about 3.5 min at the HPLC condition stated above for both sumatriptan succinate alone and for the dry mix formulation. FIGs. 6C and 6D provide UV absorbance data (200-400 nm) for the major peak observed in FIGs. 6A and FIG. 6B, respectively. In both FIGs. 6C and 6D, two peaks corresponding to 226.4 nm and 281.9 nm were observed. The UV absorbance of the solution containing drug alone (FIG. 6C) was similar to the UV
absorbance of the formulation prepared by the dry mixing method (FIG. 6D).
[0078] A wet granulate of sumatriptan succinate and sodium caprate was prepared by dissolving sodium caprate and sumatriptan succinate in a molar ratio (M) of about 2.1 in 50% alcohol/50% H20, granulating with lactose, drying, milling, mixing with other excipients and compressing into a tablet.
[0079] HPLC analysis was performed to compare the retention time for a standard solution of sumatriptan succinate alone (FIG. 7A) and a solution of the wet granulated product (FIG. 7B). The retention time for sumatriptan succinate alone was 3.479 min and the retention time for the wet mixture was 3.410 min. FIGs. 7C and 7D provide UV absorbance data (200-400 nm) for the major peak observed in FIGs. 7A and FIG. 7B, respectively. In both FIGs.
7C and 7D, two peaks corresponding to 226.4 nm and 281.9 nm were observed. The UV absorbance of the solution containing drug alone (FIG. 7C) was similar to the UV absorbance of the wet granulated product (FIG. 7D).

Example 4 Sumatriptan Patent [0080] Two in vivo dog studies were conducted. In the first study, the bioavailability of sumatriptan fast dissolving buccal tablet according to the present invention, and subcutaneous injection of sumatriptan (IMITREX, GlaxoSmithKline, United Kingdom, Brentford, Middlesex) were measured in conscious dogs (N=3). In the second study, the bioavailability of sumatriptan per-oral tablets (IMITREX, GlaxoSmithKline, United Kingdom, Brentford, Middlesex) and subcutaneous injection of sumatriptan (IMITREX, GlaxoSmithKline, United Kingdom, Brentford, Middlesex) were measured in anesthetized dogs (N=6). The dose of buccal and per-oral tablets was 25 mg per dog; the dose of subcutaneous injection was 6 mg per dog.
[0081] Male beagle dogs were used for all studies. The subcutaneous injection and per-oral tablets were commercial products under the trade name of IMITREX. Food was withheld from the dogs for a minimum of 12 hours before the study and during the study, and food was returned to them at 4 hours postdose. Water was supplied ad libitum.
[0082] Blood samples were collected from the dog's foreleg veing into heparin tubes; plasma samples were then separated at 4 C centrifuge and kept at -60 C
to -80 C until analysis. Sumatriptan was extracted from plasma via solid extraction and analyzed by LC/MS/MS. The pharmacokinetic parameters were determined using WinNonlin.
[0083] FIG. 8 shows the plasma concentration-time profiles of sumatriptan buccal tablets compared with subcutaneous and per-oral dosage forms. The buccal formulation used in the study was the fast dissolving buccal tablet of Table 6, which produced a residence time of 15 minutes in the dog buccal cavity. Table 7 shows the pharmacokinetic parameters of the evaluated sumatriptan dosage forms. In the dog studies, the fast dissolving buccal tablet displayed a significantly faster onset of Cmax than the per-oral tablet; a TmZ,, of 0.92 hr. was observed compared to 4.5 hrs in the per-oral tablets. In addition, the bioavailability of sumatriptan was increased 61% in the fast dissolving tablet compared to the per-oral tablet.

Table. 6. Formulation Composition of Sumatriptan Succinate Buccal Tablet Used in Dog Study SL # Ingredients mg/Tablet 1 Sumatriptan Succinate 35 2 Sodium Caprate 15 3 Polyethylene Glycol 8000 (PEG 8000) 26 4 Anhydrous Lactose, NF (DT Grade) 15 Poly(ethylene oxide) (Polyox 301) 6.5 6 Hydropropyl Cellulose (HPC) HXF 19 7 Talc 4 8 Aspartame 3 9 Strawberry Flavor 1.5 Total Tablet Weight (mg) 125 Residence time on dog buccal membrane 15 min Table 7. Pharmacokinetic Parameters of Sumatriptan In Vivo Dog Study (AUC values are dose-normalized) AUC Iast C max T max Ratio Administration (ng x (ng/ml) (hr) AUC/AUC
hr/ml) subcutaneous Study l (N = 3) IMITREX Subcutaneous 845 123 195 53 0.25 N/A
Injection - 6 mg Buccal Tablet - 25 mg 502 177 456 150 0.92 0.52 0.61 0.18 Study 2 (N = 6) IMITREX Subcutaneous 1007 87 213 57 0.50 0.16 N/A
Injection - 6 mg IMITREX Per-Oral 381 112 183 84 4.5 1.2 0.38 0.10 Tablet - 25 mg [0084] While the invention has been particularly shown and described with reference to some embodiments thereof, it will be understood by those skilled in the art that they have been presented by way of example only, and not limitation, and various changes in form and details can be made therein without departing from the spirit and scope of the invention. Thus, the breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents.
[0085] All documents cited herein, including journal articles or abstracts, published or corresponding U.S. or foreign patent applications, issued or foreign patents, or any other documents, are each entirely incorporated by reference herein, including all data, tables, figures, and text presented in the cited documents.

Claims (37)

1. A pharmaceutical composition for rapid transmucosal delivery comprising: sumatriptan succinate and sodium caprate, wherein a molar ratio (M) of a molar concentration of the sodium caprate to a molar concentration of the sumatriptan succinate is about 0.1 or greater, wherein absorption of the sumatriptan succinate across a biological membrane (F s) is equal to F0 + .kappa. ln(M), wherein the F0 is a steady state flux value of the absorption when the molar ratio of a molar concentration of sodium caprate to a molar concentration of sumatriptan succinate is 1, and wherein the .kappa. is an enhancement factor.
2. The composition of claim 1, wherein the molar concentration of the sodium caprate is about 1 µM to about 250 mM.
3. The composition of claim 2, wherein the molar concentration of the sodium caprate is about 10 mM to about 80 mM.
4. The composition of claim 1, wherein the molar ratio is about 0.1 to about 15.
5. The composition of claim 4, wherein the molar ratio is about 0.5 to about 10.
6. The composition of claim 1, wherein the F0 is about 100 ng/cm2/min to about 1000 ng/cm2/min.
7. The composition of claim 6, wherein the F0 is about 150 ng/cm2/min to about 950 ng/cm2/min.
8. The composition of claim 7, wherein the F0 is about 420 ng/cm2/min.
9. The composition of claim 1, wherein the .kappa. is about 1000 ng/cm2/min to about 2000 ng/cm2/min.
10. The composition of claim 9, wherein the .kappa. is about 1200 ng/cm2/min to about 1500 ng/cm2/min.
11. The composition of claim 10, wherein the .kappa. is about 1300 ng/cm2/min.
12. The composition of claim 1, wherein a regression analysis of the absorption provides a correlation coefficient (r) of about 0.9 to about 1.
13. The composition of claim 12, wherein the correlation coefficient (r) is about 0.95 to about 1Ø
14. The composition of claim 1, wherein the biological membrane is an epithelial membrane.
15. The composition of claim 1, wherein the biological membrane is a buccal mucosal membrane.
16. The composition of claim 1, wherein the composition further comprises hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, polyvinylpyrrolidone, polyethylene glycol, vegetable oil, polyols, lactose or combinations thereof.
17. The composition of claim 1, which is a mucoadhesive.
18. The composition of claim 17, wherein the mucoadhesive comprises poly(ethylene oxide), polyvinylpyrrolidone, copovidone, carbomer, polycarbophil, hydroxypropyl cellulose, hydroxyethyl cellulose, sodium carboxymethyl cellulose, polyvinyl alcohol, or combinations thereof.
19. The composition of claim 1, further comprising a diluent.
20. The composition of claim 19, wherein the diluent comprises lactose, starch, polyethylene glycol, maltodextrin, dextrose, mannitol, xylitol, other polyols or combinations thereof.
21. The composition of claim 1, wherein the composition can be administered by a non-parenteral route.
22. The composition of claim 1, which is a tablet, disk, patch, film, wafer, gel, paste, or solution dosage form.
23. A pharmaceutical composition for rapid transmucosal delivery comprising: sumatriptan succinate and an absorption enhancer, wherein a molar ratio (M) of a molar concentration of the absorption enhancer to a molar concentration of the sumatriptan succinate is about 0.1 or greater, wherein absorption of the sumatriptan succinate across a biological membrane (F s) is equal to F0 + .kappa. ln(M), wherein the F0 is a steady state flux value of the absorption when the molar ratio of a molar concentration of sodium caprate to a molar concentration of suinatriptan succinate is 1, and wherein the .kappa. is an enhancement factor.
24. The composition of claim 23, wherein the absorption enhancer comprises sodium caprate, sodium caprylate, sodium laurate, sodium lauryl sulfate or combinations thereof.
25. A method of making a pharmaceutical composition for rapid transmucosal delivery comprising sumatriptan succinate and sodium caprate, the method comprising:

mixing sumatriptan succinate and sodium caprate to form a mixture, wherein a molar ratio (M) of a molar concentration of the sodium caprate to a molar concentration of the sumatriptan succinate is about 0.1 or greater, wherein absorption of the sumatriptan succinate across a biological membrane (F s) is equal to F0 + .kappa. ln(M), wherein the F0 is a steady state flux value of the absorption when the molar ratio of a molar concentration of sodium caprate to a molar concentration of sumatriptan succinate is 1, and wherein the .kappa. is an enhancement factor.
26. The method of claim 25, further comprising compressing the mixture into a pharmaceutical composition, wherein the mixture is a dry mixture.
27. The method of claim 25, further comprising compressing the mixture into a pharmaceutical composition, wherein the mixture is a wet granulate.
28. A pharmaceutical composition made by the method of claim 25.
29. The method of claim 25, wherein the mixture is a gel, a paste, or a solution.
30. A method of making a pharmaceutical composition for rapid transmucosal delivery comprising sumatriptan succinate and sodium caprate, the method comprising:

dispersing sumatriptan succinate and sodium caprate in water or a solvent to prepare a mixture; and casting the mixture to form a pharmaceutical composition, wherein a molar ratio (M) of a molar concentration of the sodium caprate to a molar concentration of the sumatriptan succinate is about 0.1 or greater, wherein absorption of the sumatriptan succinate across a biological membrane (F s) is equal to F0 + .kappa. ln(M), wherein the F0 is a steady state flux value of the absorption when the molar ratio of a molar concentration of sodium caprate to a molar concentration of sumatriptan succinate is 1, and wherein the .kappa. is an enhancement factor.
31. The method of claim 30, wherein the mixture is spray dried to form a second mixture.
32. The method of claim 31, further comprising compressing the second mixture into a pharmaceutical composition.
33. A pharmaceutical composition made by the method of claim 30.
34. A method of treating migraine, the method comprising administering the pharmaceutical composition of claim 1 to a person in need of the treatment.
35. A method of treating cluster headache episodes, the method comprising administering the pharmaceutical composition of claim 1 to a person in need of the treatment.
36. A pharmaceutical composition for rapid transmucosal delivery comprising sumatriptan succinate and sodium caprate, wherein the molar concentration of the sodium caprate is about 1 µM to about 250 mM.
37. A pharmaceutical composition for rapid transmucosal delivery comprising sumatriptan succinate and sodium caprate, wherein the amount of sodium caprate per dosage unit is about 1 µmol to about 250 mmol.
CA002569964A 2004-06-10 2005-06-10 Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same Abandoned CA2569964A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57828604P 2004-06-10 2004-06-10
US60/578,286 2004-06-10
PCT/US2005/020745 WO2005123043A2 (en) 2004-06-10 2005-06-10 Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same

Publications (1)

Publication Number Publication Date
CA2569964A1 true CA2569964A1 (en) 2005-12-29

Family

ID=35169700

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002569964A Abandoned CA2569964A1 (en) 2004-06-10 2005-06-10 Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same

Country Status (4)

Country Link
US (1) US20060002989A1 (en)
EP (1) EP1765300A2 (en)
CA (1) CA2569964A1 (en)
WO (1) WO2005123043A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
AU2005329255B2 (en) * 2004-04-15 2010-09-30 Chiasma, Inc. Compositions capable of facilitating penetration across a biological barrier
WO2006135491A2 (en) * 2005-06-08 2006-12-21 Basf Aktiengesellschaft Medicament carrier composition and method of forming a film therefrom
GB0625322D0 (en) * 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
EA201000118A1 (en) * 2007-08-15 2010-06-30 Игорь Анатольевич Помыткин SUBLINGUAL OR TRANSBUCKCAL COMPOSITIONS CONTAINING AMBER ACID AND INTENDED FOR THE TREATMENT OF ALZHEIMER'S DISEASE
MX2010009961A (en) * 2008-03-14 2010-09-30 Cephalon Inc Enhanced transmucosal composition and dosage form.
JP5623406B2 (en) 2008-09-17 2014-11-12 キアズマ インコーポレイテッド Pharmaceutical compositions and related delivery methods
DE102008047910A1 (en) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tabletting excipient based on lactose and cellulose
NZ599344A (en) * 2009-09-25 2015-02-27 Reddy’S Lab Ltd Dr Formulations comprising triptan compounds
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
CN103940923B (en) * 2014-04-10 2015-09-23 山东省化工研究院 A kind of detection method of sumatriptan purity
AU2016215350B2 (en) 2015-02-03 2021-11-25 Amryt Endo, Inc. Method of treating diseases
US11364225B2 (en) 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR79215B (en) * 1982-06-07 1984-10-22 Glaxo Group Ltd
HU196752B (en) * 1983-12-06 1989-01-30 Glaxo Group Ltd Process for production of medical compositions containing indole-derivatives and these compounds
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
GB8419575D0 (en) * 1984-08-01 1984-09-05 Glaxo Group Ltd Chemical compounds
US4721716A (en) * 1984-08-06 1988-01-26 Neesby Torben E Method for desensitizing the gastrointestinal tract from food allergies
US5783207A (en) * 1985-05-01 1998-07-21 University Of Utah Research Foundation Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US4735967A (en) * 1985-05-28 1988-04-05 Neesby Torben E Method for desensitizing the gastrointestinal tract from food allergies
US5270333A (en) * 1986-01-28 1993-12-14 Glaxo Group Limited Indole derivatives
US5824334A (en) * 1989-09-05 1998-10-20 University Of Utah Research Foundation Tobacco substitute
GB9022250D0 (en) * 1990-10-12 1990-11-28 Glaxo Group Ltd Medicaments
GB9026998D0 (en) * 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
GB9102579D0 (en) * 1991-01-24 1991-03-27 Glaxo Group Ltd Compositions
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
GB9125699D0 (en) * 1991-12-03 1992-01-29 Glaxo Group Ltd Device
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US5942241A (en) * 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
CN1230123A (en) * 1996-07-11 1999-09-29 荷兰发马克有限公司 Inclusion complex containing indole selective serotonin agonist
US6586458B1 (en) * 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US6624138B1 (en) * 2001-09-27 2003-09-23 Gp Medical Drug-loaded biological material chemically treated with genipin
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
US20010004644A1 (en) * 1997-07-21 2001-06-21 Levin Bruce H. Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
US6432986B2 (en) * 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US7799337B2 (en) * 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
AU4894697A (en) * 1997-10-01 1999-04-23 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US6028212A (en) * 1997-12-16 2000-02-22 Morton International, Inc. Solid vinyl ether terminated urethane curing agent
US6579899B1 (en) * 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
US6255334B1 (en) * 1998-10-30 2001-07-03 Pfizer Inc 5HT 1 receptor agonists and metoclopramide for the treatment of migraine
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
CO5190664A1 (en) * 1999-06-30 2002-08-29 Pfizer Prod Inc COMBINATION THERAPY FOR THE TREATMENT OF MIGRANA ADMINISTRATION OF A 5HT RECEPTOR, CAFFEINE AND A CYCLLOXYGENASA-2 INHIBITOR
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
CA2406226A1 (en) * 2000-04-18 2001-10-25 Pharmacia Corporation Rapid-onset formulation of a selective cyclooxigenase-2
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
EP1435945B1 (en) * 2001-06-05 2008-08-13 Aung-din, Ronald Topical migraine therapy
US20030181462A1 (en) * 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
HUP0500096A3 (en) * 2001-12-19 2012-08-28 Bristol Myers Squibb Co Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function, process for producing them and pharmaceutical compositions containing them
US7015219B2 (en) * 2001-12-19 2006-03-21 Bristol-Myers Squibb Company 3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators
WO2003070273A1 (en) * 2002-02-25 2003-08-28 Lyfjathroun Hf A bioadhesive agent
US20030194420A1 (en) * 2002-04-11 2003-10-16 Richard Holl Process for loading a drug delivery device

Also Published As

Publication number Publication date
WO2005123043A2 (en) 2005-12-29
US20060002989A1 (en) 2006-01-05
EP1765300A2 (en) 2007-03-28
WO2005123043A3 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
CA2569964A1 (en) Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
US5900247A (en) Mucoadhesive pharmaceutical composition for the controlled release of active principles
EP2461795B2 (en) Sublingual and buccal film compositions
EP1504765B1 (en) Quickly soluble film preparations
Madhavi et al. Buccal film drug delivery system-an innovative and emerging technology
CA2417736A1 (en) Sildenafil citrate solid dispersions having high water solubility
CN1230123A (en) Inclusion complex containing indole selective serotonin agonist
KR20090043528A (en) Galenic formulations of aliskiren
CA2785639A1 (en) Melt extruded nicotine thin strips
KR20150063567A (en) Solid dosage form
Singh et al. Frovatriptan loaded hydroxy propyl methyl cellulose/treated chitosan based composite fast dissolving sublingual films for management of migraine
CA2717099A1 (en) Compositions and methods for transmucosal delivery of lofexidin
Kaza et al. Design and characterization of fast dissolving films of Valsartan
EP2486913A1 (en) Rapidly disintegrating oral film formulation for Olanzapin
Mahmod et al. Formulation and evaluation of Zolmitriptan bilayer oral strip
Jain et al. Design and development of a mucoadhesive buccal film bearing progesterone
KR101170548B1 (en) Improved formulations containing substituted imidazole derivatives
Balaji et al. Fast dissolving oral films for immediate drug release: a review
Ravichandiran et al. Fast dissolving tablets: A Review
Garg et al. Buccal Bioadhesive Drug Delivery Systems and Their Applications
Kaur et al. Formulation development and evaluation of fast dissolving bioadhesive sublingual film of sumatriptan
Ahmady Comparative Buccal Delivery of Cyclobenzaprine Hcl And Cyclobenzaprine (Base) Using Mucoadhesive Buccal Film.
US20240156727A1 (en) Rolled oral thin films having a high level of active-ingredient loading
Pathak et al. Recent Updates on Orally Disintegrating Thin Films
CN117956980A (en) Rapidly disintegrating oral films/foams with high active ingredient loading based on mixtures of polyvinyl alcohols having different molecular weights

Legal Events

Date Code Title Description
FZDE Discontinued